BrainsWay stock
BWAYNASDAQBrainsWay Ltd., HealthcareISIN US10501L1061
60Score 60 out of 100, Neutral
Price and trend
41 / 100
Price history
+30% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 26% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 42).
The price is 40% below its 52-week high. Largest decline in 8 years: 88% (January 2020 to May 2023).
Chart figures for advanced users
- SMA 50$12.35
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$13.88
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)42
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$7.25
- The lowest closing price of the last twelve months.
- Resistance$17.17
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- BrainsWay Ltd. belongs to the Medical (Specialties) industry (Israel) and, with a market value of $402.04M, is number 12 of 14 companies in its industry on MEQIRI.
- This is an American depositary receipt (ADR).
- In fiscal 2025 it reported revenue of $52.23M (up 27.3% year on year) and earnings of $7.63M (up 161.3%).
Show more
- MEQIRI Score 60 out of 100 (Neutral): rank 277 of 714 in Healthcare, median 53.
- The P/E is 46 (Healthcare sector median 26.7, own median of recent years 39.3).
- Our model puts fair value at $12.04, with the price 7% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $63.43M, financial debt $6.88M.Stability 68
- Share buybacksShare count down 15% since 2020.Capital allocation 54
- Earnings turn into cashFree cash flow 114% of earnings over the last 12 months.Fundamentals 58
Weaknesses
- Richly valuedP/E 46, Healthcare sector median 26.7, own median 39.3.Valuation 37
- Volatile share priceVolatility 55% a year over the last 12 months.Stability 68
Its standout strengths are profitability and growth, while technical analysis and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 58 to 60.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price far below its 52-week high
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $8.60 and expensive above $20.06 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $18.12 (cash-flow model) and $5.96 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 10.4%. At 11.4% the fair value would be $10.71, at 9.4% it would be $13.86.
Valuation metrics
Half from the cash-flow model, half from earnings times the sector P/E (26.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 33.4% on the twelve months before. Revenue has grown strongly since 2012, at around 47% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 75%, operating 8%, net 15%.
Debt & balance sheet
latest quarterLow debt, and interest is adequately covered.
Earnings
- Next earnings
- 10 Mar 2027in 118 days
- Last reported
- 10 Nov 2026below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- 0.310.0%
- Revenue
- $69.16M0.0%
- Earnings per share
- 0.510.0%
- Revenue
- $85.34M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +9.9%2026 revenue guidance raised to $68 million to $70 million (previously $66 million to $68 million), representing 30% to 34% growth.
“Looking ahead, based on our strong first half performance and continued momentum, we are raising our full year 2026 guidance from a range of $66 million to $68 million to a range of $68 million to $70 million for the full year 2026.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 12 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at BrainsWay
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 60
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Specialties)
The next larger and next smaller companies by market value
- Medacta GroupMOVE.SW $2.64B58
- Eckert & ZieglerEUZ.DE $969.93M74
- QuidelOrthoQDEL $817.18M32
- Mesa LaboratoriesMLAB $782.43M58
- Shoulder InnovationsSI $458.61M48
- Mobia MedicalMOBI $448.43M45
- 908 DevicesMASS $415.82M43
- IVF Hartmann HoldingVBSN.SW $357.26M69
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.